XPhyto Announces Psychedelic Pharmaceutical Production Agreement
Vancouver, Canada (February 3, 2021) – XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce that XPhyto Laboratories Inc. (“XPhyto Labs”), its wholly owned Alberta subsidiary, has signed an agreement (the “Agreement”) with Applied Pharmaceutical Innovation (“Applied”) for the synthesis of pharmaceutical grade psychedelic compounds and the parallel development of the standard operating procedures necessary to obtain regulatory approval for the respective commercial production process. The industrial-scale production of standardized active pharmaceutical ingredients is an important part of XPhyto’s psychedelic pharmaceutical program as the Company anticipates a shortage of large-scale supply of certain approved and standardized pharmaceutical grade psychedelics.
Applied is a not-for-profit institution at the University of Alberta created to support translational drug development for industry and innovators. With an interdisciplinary team of over 30 pharmaceutical scientists, clinicians, regulatory, patent, and market experts, Applied provides industry with access to translational science in a framework that supports commercial success. This includes retention of IP and ownership of work product for the funder, focused and efficient project execution, and regulatory compliant operations.
“In late 2020, XPhyto secured a development agreement for the industrial production of psilocybin with a leading German university. Now, with Applied Pharmaceutical Innovation, we will turn our minds to the industrial production of additional psychedelic compounds,” commented Hugh Rogers, CEO of XPhyto. “The Company plans to expand its psychedelic programs in 2021, including scalable production of pharmaceutical grade compounds, drug formulations, and clinical evaluation.”
Psychedelic compounds are a highly promising new class of drugs with strong potential for the treatment of mental health related medical conditions such as depression, anxiety, addiction, and trauma-related stress disorder. With a psilocybin production program underway in Germany, XPhyto is reviewing several other compounds as potential candidates for its first psychedelic pharmaceutical production program in Canada. Considerations include the medical indication, market demand, projected supply, competition, production process, toxicity profile, delivery method, historic use, and regulatory framework for each potential compound.
The Agreement with Applied includes the potential synthesis of a broad range of psychedelic compounds based on the dealing agreement (the “Dealing Agreement”) between XPhyto and Prof. Dr. Raimar Löbenberg, announced November 9, 2020. The Dealing Agreement is exclusive to psychedelic research carried out by Dr. Löbenberg, subject to two pre-existing contracts for R&D.
On November 3, 2020, the Company announced an agreement with a leading German university for the exclusive development of a proprietary biotechnology process for the industrial manufacture of pharmaceutical grade psilocybin.
The Company will provide further information and updates in due course.